Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25217622 | 1.00 | L3MBTL1 (0.41) | L3MBTL1RAB9AMAPTHCRTR2ALDH1A1 | |
| SCHEMBL29584483 | 0.88 | MEN1 (0.43) | RAB9AMAPTHCRTR2ALDH1A1GAA | |
| SCHEMBL18586063 | 0.88 | MEN1 (0.43) | RAB9AMAPTHCRTR2ALDH1A1GAA | |
| SCHEMBL18345004 | 0.86 | SCN9A (0.49) | SCN9A | |
| SCHEMBL6694621 | 0.86 | SCN9A (0.49) | SCN9A | |
| SCHEMBL5459736 | 0.86 | SCN9A (0.49) | SCN9A | |
| SCHEMBL4760197 | 0.86 | SCN9A (0.49) | SCN9A | |
| SCHEMBL4436548 | 0.86 | SCN9A (0.49) | SCN9A | |
| SCHEMBL6690206 | 0.85 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2NPC1KDM1A | |
| SCHEMBL6690204 | 0.85 | SMN1; SMN2 (0.46) | RAB9ASMN1; SMN2NPC1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313396-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | The Regents of The University of Michigan (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210403-A1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450492-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1910322-B1 | NOVEL DEUTERATED BENZO [D][1,3]-DIOXOL DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | CONCERT PHARMACEUTICALS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-09-02 | — | — | US | disclosed |
| US-7678914-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. | 2008-11-20 | — | — | US | disclosed |
| EP-1910322-A2 | NOVEL BENZO [D][1,3]-DIOXOL DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007016431-A2 | NOVEL BENZO [D] [1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, TPH2, HTR5A | L3MBTL1 4074/4885RAB9A 3323/4885MAPT 1222/4885 |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | L3MBTL1 3835/4885RAB9A 3001/4885MAPT 906/4885 |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | L3MBTL1 3835/4885RAB9A 3001/4885MAPT 906/4885 |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | L3MBTL1 4082/4885RAB9A 2699/4885MAPT 1006/4885 |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | L3MBTL1 4082/4885RAB9A 2699/4885MAPT 1006/4885 |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, HTR1A | L3MBTL1 4082/4885RAB9A 2699/4885MAPT 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.